

# ISAR HIGHLIGHTS (JANUARY - JULY 2025)

## ISAR ACHIEVEMENTS

We celebrate ISAR's recruitment of **34,721** patients from **29** countries, as well as the achievement of **35** publications and **63** abstracts and posters. We thank all our ISAR collaborators for their contributions!



## ISAR PUBLICATIONS

There are **seven** ISAR publications so far in 2025, including **SOLAR II** (published in the Blue Journal).



### CLEAR

Biologic continuers had fewer exacerbations, lower long-term OCS use and better asthma control than switchers or stoppers at follow-up.

[Full article](#) | [Press release](#) | [Slide deck](#)



### STAR

OCS (intermittent or long-term) use affects BEC distribution and disease burden was high among long-term OCS users irrespective of BEC.

[Full article](#) | [Press release](#) | [Slide deck](#)



### ISAR progress update

ISAR's origins, Delphi studies, research, ongoing quality improvement initiatives, and vision for the future are summarized.

[Full article](#)



### SOLAR I

Biologic initiation in patients with severe asthma led to substantial reduction in total OCS exposure, particularly in the first year.

[Full article](#) | [Press release](#) | [Slide deck](#)



### Biologic choice and timing

There was weak interobserver agreement among asthma specialists in initiating biologics and selecting treatment.

[Full article](#)



### SOLAR II

Biologics prevent new-onset OCS-related adverse outcomes (including diabetes, major cardiovascular events and anxiety/depression) in patients with severe asthma.

[Full article](#) | [Press release](#) | [Slide deck](#)



### Exacerbation prediction

T2 and non-T2 inflammatory pathways predict severe asthma exacerbations.

[Full article](#) | [Press release](#) | [Slide deck](#)

## UPCOMING ISAR EVENTS AT ERS 2025



### Saturday 27 September, Hotel Okura, Amsterdam

**14:30 - 15:00 ISAR Steering Committee + MOONLIGHT** working group meeting

- *MOONLIGHT: Impact of biologics on inhaled corticosteroid reduction*

**15:00 - 15:30 SPOTLIGHT** working group meeting

- *SPOTLIGHT: Impact of remission on long-term clinical outcomes*

**15:45 - 16:30 ISAR Quality Improvement + ENLIGHTEN** working group meeting

- *ENLIGHTEN: Assessment of quality improvement in ISAR*

**16:45 - 17:30 Research Updates + SHINE** working group meeting

- *SHINE: Maintenance of long-term remission and the causes of secondary failure to biologics*

**17:30 - 19:00 Reception**

*The ISAR team will share the invitations to these meetings with the ISAR collaborators.*

# ISAR EVENTS (JANUARY - JULY 2025)



58

collaborators  
from

28

countries attended  
ISAR events (in  
person and online)

20

country  
meetings

6

ISAR Session  
presentations

## Highlights of the ISAR meetings

- ISAR research projects of 2025 were introduced: **SHINE** (ISC-prioritized) and **MOONLIGHT** (AZ-prioritized).
- Ideas for the long-term sustainability of ISAR were discussed at the ISC meeting and country meetings.
- Project updates for the ISAR research projects of 2024, **GLEAM** and **SPOTLIGHT**, were presented.
- New dashboards on long-term OCS use were showcased, and ideas for practice change were discussed.

## ISAR Session (co-chaired by David Price and Veronica Mendez)

- Luis Perez-de-Llano presented exciting findings from **FULL BEAM II**: patients with less severe disease and shorter duration of asthma pre-biologic-initiation had a better chance of achieving remission post-biologic.
- Walter Canonica and Victoria Carter introduced the **GLEAM** and **SPOTLIGHT** studies.
- Désirée Larenas-Linnemann and Celine Goh discussed practice change in severe asthma management.
- Piotr Kuna presented **SOLAR II**, which looks at OCS-related outcomes and biologics in severe asthma.
- Pujan Patel and Freya Tyrer presented the trend of reducing/stopping long-term OCS use among ISAR patients.



# ATS 2025

16-21 MAY

SAN FRANCISCO, UNITED STATES

## Highlights of the ISAR meetings

- Project updates for **SPOTLIGHT**, **SHINE** and **MOONLIGHT** were presented.
- ISAR's quality improvement goal of 2025, the elimination of long-term OCS and frequent intermittent OCS use, was discussed.
- **Upcoming quality improvement tools** were showcased:
  - REDCap Lite streamlines the clinical consultation form to a single page and encourages broader use of REDCap as a clinical tool
  - ISAR OCS risk calculator predicts health risks linked to OCS use in patients with asthma.

23

collaborators  
attended ISAR  
events (in person  
and online)SOLAR  
IIlate-breaking  
poster and  
journal session  
presentation